- Home
- CLRB vs NERV Comparison
CLRB vs NERV Comparison
Compare CLRB & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- NERV
- Stock Information
- Founded
- CLRB 2002
- NERV 2007
- Country
- CLRB United States
- NERV United States
- Employees
- CLRB N/A
- NERV N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- NERV Health Care
- Exchange
- CLRB Nasdaq
- NERV Nasdaq
- Market Cap
- CLRB 14.2M
- NERV 12.0M
- IPO Year
- CLRB N/A
- NERV 2014
- Fundamental
- Price
- CLRB $4.44
- NERV $1.76
- Analyst Decision
- CLRB Hold
- NERV Hold
- Analyst Count
- CLRB 2
- NERV 1
- Target Price
- CLRB N/A
- NERV $5.00
- AVG Volume (30 Days)
- CLRB 113.2K
- NERV 21.0K
- Earning Date
- CLRB 08-14-2025
- NERV 08-19-2025
- Dividend Yield
- CLRB N/A
- NERV N/A
- EPS Growth
- CLRB N/A
- NERV N/A
- EPS
- CLRB N/A
- NERV 0.83
- Revenue
- CLRB N/A
- NERV N/A
- Revenue This Year
- CLRB N/A
- NERV N/A
- Revenue Next Year
- CLRB N/A
- NERV N/A
- P/E Ratio
- CLRB N/A
- NERV $2.20
- Revenue Growth
- CLRB N/A
- NERV N/A
- 52 Week Low
- CLRB $4.36
- NERV $1.15
- 52 Week High
- CLRB $68.70
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- CLRB 35.40
- NERV 42.32
- Support Level
- CLRB $4.72
- NERV $1.79
- Resistance Level
- CLRB $5.09
- NERV $1.88
- Average True Range (ATR)
- CLRB 0.38
- NERV 0.09
- MACD
- CLRB 0.09
- NERV -0.03
- Stochastic Oscillator
- CLRB 3.42
- NERV 0.00
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.